Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
- Authors
- Peter BrossJulie BeitzGang ChenXi ChenEamon Duffy
- Journal
- PubMed
In The Last Decade
doi.org/w22610007 →Countries where authors are citing Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
This map shows the geographic impact of Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. more than expected).
Fields of papers citing Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
This network shows the impact of Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia..
About Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
This paper, published in 2001, received 660 indexed citations . Written by Peter Bross, Julie Beitz, Gang Chen, Xi Chen, Eamon Duffy, Sandip Kumar Roy, R N Sridhara, Atiqur Rahman, Grant Williams and Richard Pazdur covering the research area of Oncology, Genetics and Hematology. It is primarily cited by scholars working on Oncology (326 citations), Hematology (262 citations) and Radiology, Nuclear Medicine and Imaging (256 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w22610007.